New Research on Alopecia Areata Reveals Vast Potential for Eli Lilly’s Recently Approved Olumiant Across Both the US and EU5, According to Spherix Global Insights

US and EU5 dermatologists report the availability of an oral JAK inhibitor would make a significant change in their treatment decisions moving forward EXTON, Pa., June 22, 2022 /PRNewswire/ — Spherix recently surveyed 200 EU-based dermatologists across France, Germany, Italy, Spain, and…

Click here to view original post